# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the Secretary

# Office for Civil Rights; Statement of Delegation

In accordance with Executive Order 13798 Promoting Free Speech and Religious Liberty (May 4, 2017), 82 FR 21675, and the Attorney General's Guidance on Federal Law Protections for Religious Liberty (October 6, 2017), notice is hereby given that I have delegated to the Director of the Office for Civil Rights (OCR), or his or her successor, authority over implementation of and compliance with the Religious Freedom Restoration Act (RFRA), 42 U.S.C. 2000bb et seq., relating to programs or activities funded, conducted, or administered by the Department.

Pursuant to this delegation, the OCR Director shall have the authority to:

- (1) Accept and investigate complaints filed by individuals or entities alleging a failure by any departmental component to comply with RFRA;
- (2) conduct RFRA compliance reviews of departmental programs or activities;
- (3) provide technical assistance to departmental components regarding RFRA compliance;
- (4) evaluate the effectiveness of RFRA complaint processing by OCR and provide reports to appropriate oversight organizations; and
- (5) initiate such other actions as may be necessary to facilitate and ensure compliance with RFRA.

This authority may be redelegated. If the OCR Director chooses to redelegate this authority, the OCR Director will maintain primary responsibility and accountability for implementation of this section. This delegation is effective upon date of signature. I hereby affirm and ratify any actions taken by the Director of OCR or subordinates which involved the exercise of the authorities delegated herein prior to the effective day of this delegation.

Dated: December 7, 2017.

#### Eric D. Hargan,

Acting Secretary, Department of Health and Human Services.

[FR Doc. 2018–00816 Filed 1–18–18; 8:45 am]

BILLING CODE 4153-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Office of the Secretary

# Office for Civil Rights; Statement of Delegation

Notice is hereby given that I have delegated to the Director of the Office for Civil Rights, or his or her successor, the authorities vested in the Secretary concerning enforcement of and compliance with Section 1303(b)(4) of the Patient Protection and Affordable Care Act, 42 U.S.C. 18023(b)(4). This delegation transfers, but only for the authorities pursuant to Section 1303(b)(4) and not for other authorities under Section 1303, the previous delegation to the Administrator, Centers for Medicare & Medicaid Services, or his or her successor, noticed at 76 FR 53903 (Aug. 30, 2011).

Pursuant to this delegation, the OCR Director shall have the authority to:

- (1) Accept and investigate complaints filed by individuals or entities alleging a failure to comply with Section 1303(b)(4);
- (2) conduct Section 1303(b)(4) compliance reviews;
- (3) provide technical assistance to departmental components and qualified health plans regarding Section 1303(b)(4) compliance;
- (4) evaluate the effectiveness of subsection 1303(b)(4) complaint processing by OCR and provide reports to appropriate oversight organizations; and
- (5) initiate such other actions as may be necessary to facilitate and ensure compliance with Section 1303(b)(4).

This authority may be redelegated. If the OCR Director chooses to redelegate this authority, the OCR Director will maintain primary responsibility and accountability for implementation of this section. This delegation is effective upon date of signature. I hereby affirm and ratify any actions taken by the Director of OCR or subordinates which involved the exercise of the authorities delegated herein prior to the effective day of this delegation.

Dated: December 7, 2017.

#### Eric D. Hargan,

Acting Secretary, Department of Health and Human Services.

[FR Doc. 2018-00818 Filed 1-18-18; 8:45 am]

BILLING CODE 4153-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Cognition and Perception Study Section.

Date: February 8–9, 2018. Time: 8:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites Baltimore, Inner Harbor, 222 St. Paul Place, Baltimore, MD 21202.

Contact Person: Andrea B. Kelly, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3184, MSC 7770, Bethesda, MD 20892, (301) 455– 1761, kellya2@csr.nih.gov.

Name of Committee: Biobehavioral and Behavioral Processes Integrated Review Group; Adult Psychopathology and Disorders of Aging Study Section.

Date: February 12–13, 2018. Time: 8:30 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Ritz-Carlton Hotel at Pentagon City, 1250 South Hayes Street, Arlington, VA 22202

Contact Person: Serena Chu, Ph.D., Scientific Review Officer, BBBP IRG, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3178, MSC 7848, Bethesda, MD 20892, (301) 500– 5829, sechu@csr.nih.gov.

Name of Committee: Endocrinology, Metabolism, Nutrition and Reproductive Sciences Integrated Review Group; Cellular Aspects of Diabetes and Obesity Study Section.

Date: February 13–14, 2018. Time: 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Ritz-Carlton Hotel, 1700 Tysons Boulevard, McLean, VA 22102.

Contact Person: Antonello Pileggi, MD, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institute of